Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of bevacizumab-expressing oncolytic herpesvirus T-BV in recurrent malignant glioma
jRCT2033250552Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T-BV in malignant glioma, glioblastoma (GBM) and astrocytoma, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety. Started Jun 2026; status: recruiting.
02
Drugs
T-BV
03
Conditions
malignant gliomaglioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on jRCT2033250552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250552.